A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer (ABC). PANGEA-Breast.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PANGEA-Breast
- 22 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 May 2017.
- 01 Feb 2017 New source identified and integrated: ClinicalTrials.gov: US National Institutes of Health record (NCT03025880).
- 12 Jan 2017 New trial record